论文部分内容阅读
目的探讨应用重组组织型纤溶酶原激活剂(recombinant tissue plasminogen activator,rt-PA)静脉溶栓联合丹参注射剂治疗急性脑梗死的疗效。方法将120例发病<4.5 h的急性脑梗死患者分为治疗组和对照组,每组60例。治疗组应用rt-PA静脉溶栓联合丹参注射液治疗,对照组应用rt-PA静脉溶栓治疗。对比两组患者治疗后美国国立卫生院神经功能缺损评分(national institutes of health stroke scale,NIHSS)、Ranking评分及脑梗死面积。结果治疗组NIHSS评分、Ranking评分明显降低,脑梗死面积明显缩小,与对照组差异有统计学意义。结论对发病<4.5 h的急性脑梗死患者,rt-PA静脉溶栓联合丹参注射剂治疗具有积极意义。
Objective To investigate the curative effect of intravenous thrombolysis combined with Danshen injection on acute cerebral infarction by using recombinant tissue plasminogen activator (rt-PA). Methods 120 patients with acute cerebral infarction <4.5 h were divided into treatment group and control group, 60 cases in each group. Treatment group rt-PA intravenous thrombolysis combined with Salvia injection, the control group rt-PA intravenous thrombolytic therapy. The National Institutes of Health Stroke Scale (NIHSS), Ranking score and infarct size were compared between the two groups after treatment. Results The NIHSS score, Ranking score of the treatment group decreased significantly, the area of cerebral infarction was significantly reduced, and the difference was statistically significant with the control group. Conclusion For patients with acute cerebral infarction <4.5 h, rt-PA intravenous thrombolysis combined with Salvia injection has a positive effect.